Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCIA Combined With Different Opioid Receptors for Gastrointestinal Surgery
NCT05576675Phase 3Completed
- Sponsor
- Xijing Hospital
- Start
- May 2018
- Primary completion
- Mar 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3 trial of nalbuphine, hydromorphone and sufentanil in postoperative pain (3 arms), sponsored by Xijing Hospital. Primary endpoint: Incidence of insufficient static and dynamic analgesia at 48 hours. Started May 2018; status: completed.
02
Drugs
nalbuphinehydromorphonesufentanil
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05576675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576675.